- Details
- Michael Morris, MD, and Christopher Sweeney, MBBS join Alicia Morgans, MD, MPH in a discussion on the treatment of metastatic hormone-sensitive prostate cancer. Dr. Sweeney shares his perspective on the use of combination therapy, in addition to traditional ADT, and how he approaches treatment decisions Dr. Morris discusses the latest data in this space coming from the CHAARTED and STAMPEDE studie...
|
- Details
- Tom Keane welcomes Evan Yu to discuss the newest therapeutic options for patients with metastatic hormone-sensitive prostate cancer. Dr. Yu details the most crucial studies to date demonstrating improved OS in mHSPC patients, including the ARCHES , ENZAMET , STAMPEDE , and TITAN clinical trials. Additionally, he touches on the survival benefit shown in the CHAARTED trial. Dr. Yu provides a compreh...
|
- Details
- Christopher Sweeney joins Charles Ryan to discuss the topic of hormone-sensitive prostate cancer, specifically concentrating on how clinicians can confront and categorize their patients with the disease. In continuing the ongoing conversation of the optimal approach for a high-volume patient, Dr. Sweeney uses evidence from current clinical trials to outline optional alternatives to abiraterone tre...
|
- Details
- In this conversation, Neeraj Agarwal joins Petros Grivas to discuss the Patient-Reported Outcomes (PRO) data from the TITAN study, Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. This data was presented at ESMO 2019. The Food and Drug Administration approved apalutamide (ERLEADA, Janssen Biotech, Inc) for patients with metastatic hormone-sensitive prostate cancer. (mHSPC) in Sept...
|
- Details
- Brenda Martone invites Alicia Morgans to share details on the upcoming Prostate Cancer Awareness Month event in Chicago, put on by Us TOO International, the 15th Annual SEA Blue Chicago Prostate Cancer Walk and Run. SEA Blue is a celebration of life, of those who have risen to the challenge to fight prostate cancer, of the lives that have been lost to the disease, and of the people we will help to...
|
- Details
- Chris Sweeney, MD and Mary-Ellen Taplin, MD discuss their current approach to treating patients with metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Sweeney first evaluates whether or not the patient is fit for chemotherapy and what their access is to abiraterone which both have a clear benefit in high volume disease. Based on the CHAARTED data, Dr. Taplin does not offer chemotherapy in...
|
- Details
- Petros Grivas invites Neeraj Agarwal to discuss the TITAN trial which reported the first interim analysis at ASCO 2019. The TITAN trial is a "Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With metastatic hormone-sensitive prostate cancer (mHSPC). A total of 525 patients were assigned to receive apalutamide plus ADT and 527 to receive placebo plus ADT. The...
|
- Details
- Kim Chi, MD discusses the first results from TITAN, A phase 3 randomized, placebo-controlled, double-blind study of apalutamide (APA) versus placebo (PBO) in men with metastatic hormone-sensitive prostate cancer (mHSPC), with Michael Morris, MD, and Alicia Morgans, MD. TITAN was designed to accrue patients with prior treatment for localized prostate cancer or prior docetaxel for mHSPC were allowed...
|
- Details
- Mary-Ellen Taplin and Alicia Morgans discuss treatment strategies in newly diagnosed metastatic prostate cancer patients. They review trial results and upcoming data that is expected to be reported out in the near future. Monotherapy with ADT is no longer the standard of care. They also discuss sequencing strategies in men who have progressed on therapy. Biographies: Mary-Ellen Taplin, MD, Chair,...
|
- Details
- Alicia Morgans, MD reviews her recent presentation in a conversation with Charles Ryan, MD. Her presentation covers three main topics including systemic therapies, treatment of the primary, and metastases directed therapy. The three main goals of therapy include delay time to progression, delay the other important goals, delay time to initiation of systemic therapy, and ultimately cure, especially...
|